Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.

Abstract:: Background: Few biomarkers of ovarian cancer prognosis have been established, partly because subtype-specific associations might be obscured in studies combining all histopathological subtypes. We examined whether tumour expression of the progesterone receptor (PR) and oestrogen receptor (ER) was associated with subtype-specific survival. Methods: 12 studies participating in the Ovarian Tumor Tissue Analysis consortium contributed tissue microarray sections and clinical data to our study. Participants included in our analysis had been diagnosed with invasive serous, mucinous, endometrioid, or clear-cell carcinomas of the ovary. For a patient to be eligible, tissue microarrays, clinical follow-up data, age at diagnosis, and tumour grade and stage had to be available. Clinical data were obtained from medical records, cancer registries, death certificates, pathology reports, and review of histological slides. PR and ER statuses were assessed by central immunohistochemistry analysis done by masked pathologists. PR and ER staining was defined as negative (

Authors:: W Sieh, M Köbel, TA Longacre, DD Bowtell, A deFazio, MT Goodman, E Høgdall, S Deen, N Wentzensen, KB Moysich, JD Brenton, BA Clarke, U Menon, CB Gilks, A Kim, J Madore, S Fereday, J George, L Galletta, G Lurie, LR Wilkens, ME Carney, PJ Thompson, RK Matsuno, SK Kjær, A Jensen, C Høgdall, KR Kalli, BL Fridley, GL Keeney, RA Vierkant, JM Cunningham, LA Brinton, HP Yang, ME Sherman, M García-Closas, J Lissowska, K Odunsi, C Morrison, S Lele, W Bshara, L Sucheston, M Jimenez-Linan, K Driver, J Alsop, M Mack, V McGuire, JH Rothstein, BP Rosen, MQ Bernardini, H Mackay, A Oza, EL Wozniak, E Benjamin, A Gentry-Maharaj, SA Gayther, AV Tinker, LM Prentice, C Chow, MS Anglesio, SE Johnatty, G Chenevix-Trench, AS Whittemore, PDP Pharoah, EL Goode, DG Huntsman, SJ Ramus

Themes